CancerPMTNCT02355171
Personalize My Treatment (PMT) Registry
An observational study of Cancer, run by Sir Mortimer B. Davis - Jewish General Hospital at 14 sites in Canada.
Trial summary
The 'Personalize My treatment' (PMT) platform is a novel form of biobanking in which cancer patients willingly consent to provide residual, clinical samples (surplus after diagnostic testing) of their tumors for cancer research, to give access to their medical record for data collection and then followed prospectively… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- How many people
- 20,000 participants
- Where
- 14 sitesCanada
- Study dates
- Nov 2015to Dec 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Cancer patients with all solid tumor types.
Age of majority in the province of recruitment.
Trial locations and contacts
14 sites in 1 country. Contact the study team or a site near you to ask about taking part.
14 sites in 1 country
Canada14 sites, 1 recruiting
- Suspended
Tom Baker Cancer Centre
Calgary, Alberta, T2N 4N2
- Suspended
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
- Suspended
QE II Health Sciences Centre
Halifax, Nova Scotia, B3H 1V8
- Suspended
London Health Science Centre
London, Ontario
- Suspended
Centre Hospitalier Universitaire Dr-Georges-L.-Dumont
Moncton, New Brunswick, E1C 2Z3
- Suspended
The Moncton Hospital
Moncton, New Brunswick, E1C 6Z8
- Suspended
Centre hospitalier de l'Université de Montréal
Montreal, Quebec, H2X 0A9
- Recruiting
Jewish General Hospital University Health Centre
Montreal, Quebec, H3T 1E2
Cyrla Hoffert, MSc., 514-340-8222 ext. 27992, cyrla.hoffert@ladydavis.ca
Mark Basik, MD
- Suspended
MUHC McGill University Health Center
Montreal, Quebec, H4A 3J1
- Suspended
The Ottawa Hospital
Ottawa, Ontario, K1H 8L6
- Suspended
Centre hospitalier universitaire de Québec - Université Laval
Québec, Quebec, H3T 1Y6
- Suspended
Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, J1G 2E8
- Suspended
Odette Cancer Centre - Sunnybrook Hospital
Toronto, Ontario, M4N 3M5
- Suspended
CIUSSS de la Mauricie-et-du-Centre-du-Québec - Centre Hospital Régional
Trois-Rivières, Quebec, G8Z 3R9
About this study
Official title: A Longitudinal Oncology Registry at the Jewish General Hospital University Health Centre
The 'Personalize My treatment' (PMT) platform is a novel form of biobanking in which cancer patients willingly consent to provide residual, clinical samples (surplus after diagnostic testing) of their tumors for cancer research, to give access to their medical record for data collection and then followed prospectively throughout the trajectory of their illness. They further willingly consent to be recontacted for being informed of other research projects, including clinical trials.
- Conditions
- Cancer
- Medical subject headings
- Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary objective of PMT is to create a collection of cancer patient biospecimens and annotated data that will be used for clinical trial matching and to advance cancer research.
Measured: Longitudinal
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2015 (estimated)
- Study startNov 2015
- Primary completionDec 2030 (estimated)
- Study completionDec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Other
- Enrolment
- 20,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Lady Davis Institute, McGill Centre for Translational Research in Cancer
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02355171
- Sponsor's protocol ID
- PMT
- Acronym
- PMT
- Status last verified
- Nov 2026
- First submitted
- 30 Jan 2015
- Last updated
- 5 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Yes: The BDAC (Biospecimen and Data Access Committee) authorizes access requests from researchers to the PMT Platform's biospecimens and data. It meets as needed to review requests in accordance with the PMT Biospecimen and Data Access Policy. Requests will be evaluated based on scientific merit, availability of sample and alignment with the mission of the PMT Platform and Exactis. BDAC is responsible for verifying that the proposed project has received appropriate ethics approval and proof of such approval has been provided.
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Longitudinal Oncology Registry at the Jewish General Hospital University Health Centre
- ClinicalTrials.gov ID
- NCT02355171
- Acronym / sponsor ID
- PMT / PMT
- Conditions
- Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 20,000 participants (estimated)
- Lead sponsor
- Sir Mortimer B. Davis - Jewish General HospitalUniversity, hospital or other
- Collaborators
- Lady Davis Institute, McGill Centre for Translational Research in Cancer
- Study start
- Nov 2015
- Primary completion
- Dec 2030 (estimated)
- Study completion
- Dec 2030 (estimated)
- First posted
- 4 Feb 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The 'Personalize My treatment' (PMT) platform is a novel form of biobanking in which cancer patients willingly consent to provide residual, clinical samples (surplus after diagnostic testing) of their tumors for cancer research, to give access to their medical record for data collection and then followed prospectively throughout the trajectory of their illness. They further willingly consent to be recontacted for being informed of other research projects, including clinical trials.
Study design
- Observational model
- Cohort
- Time perspective
- Other
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Cancer patients with all solid tumor types.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The primary objective of PMT is to create a collection of cancer patient biospecimens and annotated data that will be used for clinical trial matching and to advance cancer research.
Time frame: Longitudinal
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. The BDAC (Biospecimen and Data Access Committee) authorizes access requests from researchers to the PMT Platform's biospecimens and data. It meets as needed to review requests in accordance with the PMT Biospecimen and Data Access Policy. Requests will be evaluated based on scientific merit, availability of sample and alignment with the mission of the PMT Platform and Exactis. BDAC is responsible for verifying that the proposed project has received appropriate ethics approval and proof of such approval has been provided.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
14 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by Sir Mortimer B. Davis - Jewish General Hospital at 14 sites in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 14 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Gerald Batist, MD (514-340-8222 ext. 25418, gerald.batist.med@ssss.gouv.qc.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary objective of PMT is to create a collection of cancer patient biospecimens and annotated data that will be used for clinical trial matching and to advance cancer research. (time frame: Longitudinal). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.